ClinicalTrials.gg
CompletedNCT05358717Updated Jun 16, 2026Results posted

A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

A Phase 2 interventional study of PTC518 and Placebo in Huntington Disease, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in 11 countries. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.

Enrollment
20th of 90
159 · median 44
Started
2022
with 6 others
Phase 2
28 of 138
none open now
Registered
111th of 138
by date

Among the 138 studies in Huntington Disease with a site in United States, this one is the 20th largest by enrollment of the 90 interventional ones that give a count, is one of 7 that started in 2022, is one of 28 in phase 2, and was the 111th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Huntington Disease with a site in United States, or all of them as a file.
02

Study summary

The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.

Read the detailed description

Participants will first be randomized to Part A or Part B or Parts D or E in a 1:1 randomization ratio, depending on their Huntington's disease Integrated Staging System (HD-ISS) staging criteria and then to active treatment (PTC518 5 mg in Parts A and D and 10 mg in Parts B and E) or matching placebo within each part in a 2:1 ratio of active treatment to placebo. A Drug Safety Monitoring Board (DSMB) Charter will undertake an unblinded review of safety data from the 5 and 10 mg dosing groups and provide a recommendation on when Parts C and F (with a 20 mg active treatment arm) can be initiated. At that time, participants will be randomized to any study Part that is currently open for enrollment, and then to either active treatment or placebo (in a 2:1 ratio) within that Part.

Participants who complete this study and agree to participate in a long-term extension (LTE) study, will be enrolled in a separate LTE study PTC518-CNS-004-HD (NCT06254482).

03

Conditions studied

  • Huntington Disease

Keywords

  • Neurodegenerative disorder
  • Rare disease
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length from 40 to 50, inclusive

Eligibility for HD-ISS Stage 2 Group (Parts A, B, and C):

  • A Unified Huntington's Disease Rating Scale (UHDRS)-Independence Scale (IS) score of 100
  • A UHDRS Total Functional Capacity (TFC) score of 13
  • A score between 0.18 and 4.93 inclusive on the normed version of the HD prognostic index (PINHD)

Eligibility for HD-ISS Mild Stage 3 Group (Parts D, E, and F):

  • A UHDRS Total Functional Capacity (TFC) score of 11 or 12, or a UHDRS TFC score of 13 with an UHDRS IS score of \<100

Key Exclusion Criteria:

  • Receipt of an experimental agent within 90 days or 5 half-lives prior to Screening or anytime over the duration of this study, ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-targeted HD-specific agents such as antisense oligonucleotides, cell transplantation, or any other experimental brain surgery
  • Any history of gene therapy exposure for the treatment of HD
  • Participation in an investigational study or investigational paradigm (such as exercise/physical activity, cognitive therapy, brain stimulation, etc) within 90 days prior to Screening or anytime over the duration of this study
  • Any medical history of brain or spinal disease that would interfere with the lumbar puncture process safety assessments
  • Any medical history or condition that would interfere with the ability to complete the protocol-specified assessments (for example, implanted shunt, conditions precluding magnetic resonance imaging [MRI] scans)
  • Pregnancy, planning on becoming pregnant during the course of the study or within 6 months of end of treatment, or currently breastfeeding

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    PTC518 5 mg

    Participants will receive PTC518 5 milligrams (mg) tablets once daily orally for 12 months.

    Drug: PTC518

  • Experimental
    PTC518 10 mg

    Participants will receive PTC518 10 mg tablets once daily orally for 12 months.

    Drug: PTC518

  • Experimental
    PTC518 20 mg

    Participants will receive PTC518 20 mg tablets once daily orally for 12 months.

    Drug: PTC518

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to PTC518 tablets once daily orally for 12 months.

    Drug: Placebo

Interventions

  • DrugPTC518

    PTC518 will be administered per dose and schedule specified in the arm.

  • DrugPlacebo

    Placebo matching to PTC518 will be administered per schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug. A summary of other non-serious AEs and all serious adverse events (SAEs), regardless of causality is located in the 'Reported AE section'.

    Time frame: Baseline up to Month 18

  2. Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3

    Least square (LS) mean and 95% confidence interval (CI) were calculated using mixed-model repeated measures (MMRM). The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

    Time frame: Baseline, Month 3

Secondary outcomes

  1. Percent Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 12

    LS mean and standard error (SE) were calculated using MMRM.

    Time frame: Baseline, Month 12

  2. Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 12

    cUHDRS includes the Total Functional Capacity (range, 0-13; higher score means better functioning), Total Motor Score (range, 0-124; higher score means worse motor severity), Symbol Digit Modality Test (range, 0-110, correctly paired numbers-symbols in 90 seconds; higher score means better cognitive performance), and Stroop Word Reading (range, 0-no max value, correctly read colour words in 45 seconds; higher score means better cognitive performance) scores. The total score for the cUHDRS ranges from approximately 3 to 18, where higher scores indicated better functioning. LS mean and SE were calculated using analysis of covariance (ANCOVA) model.

    Time frame: Baseline, Month 12

  3. Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 12

    LS mean and 95% CI were calculated using MMRM. The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

    Time frame: Baseline, Month 12

  4. Percent Change From Baseline in Cerebrospinal Fluid (CSF) Mutant Huntingtin Protein (mHTT) at Month 12

    LS mean and 95% CI were calculated using MMRM. The CSF mHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

    Time frame: Baseline, Month 12

  5. Percent Change From Baseline in Blood mHTT Protein at Month 12

    LS mean and 95% CI were calculated using MMRM. The blood mHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

    Time frame: Baseline, Month 12

07

Results

Posted Jan 13, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboPTC518 5 mgPTC518 10 mg
Started535254
Received at least 1 dose of study drug535254
Completed514751
Not completed253
Withdrew: Adverse event011
Withdrew: Death110
Withdrew: Withdrawal by subject112
Withdrew: Study paused by sponsor in united states020

Outcome measures

SecondaryPercent Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 12

LS mean and standard error (SE) were calculated using MMRM.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 12
percent changePlaceboPTC518 5 mgPTC518 10 mg
Percent Change From Baseline in Caudate Volume as Assessed Via Volumetric Magnetic Resonance Imaging (vMRI) at Month 124.42 ± 0.4134.99 ± 0.4135.74 ± 0.391
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug. A summary of other non-serious AEs and all serious adverse events (SAEs), regardless of causality is located in the 'Reported AE section'.

Time frame:
Baseline up to Month 18
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlaceboPTC518 5 mgPTC518 10 mg
Number of Participants With Treatment-emergent Adverse Events (TEAEs)464349
PrimaryPercent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3

Least square (LS) mean and 95% confidence interval (CI) were calculated using mixed-model repeated measures (MMRM). The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

Time frame:
Baseline, Month 3
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3
percent changePlaceboPTC518 5 mgPTC518 10 mg
Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 3-1.40 ± -7.25-17.36 ± -22.36-28.67 ± -32.74
Statistical analysis
  • Placebo vs PTC518 5 mg · Mixed Models Analysis · p = < 0.0001 · Ls mean difference: -15.97 · 95% CI -23.59 to -8.34
  • Placebo vs PTC518 10 mg · Mixed Models Analysis · p = < 0.0001 · Ls mean difference: -27.28 · 95% CI -34.45 to -20.10
SecondaryChange From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 12

cUHDRS includes the Total Functional Capacity (range, 0-13; higher score means better functioning), Total Motor Score (range, 0-124; higher score means worse motor severity), Symbol Digit Modality Test (range, 0-110, correctly paired numbers-symbols in 90 seconds; higher score means better cognitive performance), and Stroop Word Reading (range, 0-no max value, correctly read colour words in 45 seconds; higher score means better cognitive performance) scores. The total score for the cUHDRS ranges from approximately 3 to 18, where higher scores indicated better functioning. LS mean and SE were calculated using analysis of covariance (ANCOVA) model.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 12
units on a scalePlaceboPTC518 5 mgPTC518 10 mg
Change From Baseline in Composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores at Month 12-0.64 ± 0.168-0.61 ± 0.176-0.92 ± 0.164
SecondaryPercent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 12

LS mean and 95% CI were calculated using MMRM. The blood tHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

Time frame:
Baseline, Month 12
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 12
percent changePlaceboPTC518 5 mgPTC518 10 mg
Percent Change From Baseline in Geometric Mean Blood tHTT Protein at Month 128.19 ± 1.99-14.18 ± -19.25-28.44 ± -32.45
SecondaryPercent Change From Baseline in Cerebrospinal Fluid (CSF) Mutant Huntingtin Protein (mHTT) at Month 12

LS mean and 95% CI were calculated using MMRM. The CSF mHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

Time frame:
Baseline, Month 12
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Cerebrospinal Fluid (CSF) Mutant Huntingtin Protein (mHTT) at Month 12
percent changePlaceboPTC518 5 mgPTC518 10 mg
Percent Change From Baseline in Cerebrospinal Fluid (CSF) Mutant Huntingtin Protein (mHTT) at Month 12-15.64 ± -26.71-23.68 ± -33.97-23.28 ± -32.84
SecondaryPercent Change From Baseline in Blood mHTT Protein at Month 12

LS mean and 95% CI were calculated using MMRM. The blood mHTT protein value was log-transformed before fitting the MMRM model. The LS means from MMRM model were back-transformed to present geometric mean percent changes.

Time frame:
Baseline, Month 12
Reported as:
Geometric mean · percent change
Percent Change From Baseline in Blood mHTT Protein at Month 12
percent changePlaceboPTC518 5 mgPTC518 10 mg
Percent Change From Baseline in Blood mHTT Protein at Month 1213.89 ± 6.33-14.11 ± -19.99-28.20 ± -32.89

Adverse events

Collected over Baseline up to Month 18. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/53 (1.9%)4/53 (7.5%)32/53 (60.4%)
PTC518 5 mg1/52 (1.9%)1/52 (1.9%)34/52 (65.4%)
PTC518 10 mg0/54 (0%)2/54 (3.7%)41/54 (75.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboPTC518 5 mgPTC518 10 mg
DrowningGeneral disorders and administration site conditions0/531/520/54
Atrial fibrillationCardiac disorders1/530/520/54
Vestibular disorderEar and labyrinth disorders1/530/520/54
Inguinal herniaGastrointestinal disorders1/530/520/54
Road traffic accidentInjury, poisoning and procedural complications1/530/520/54
Wrist fractureInjury, poisoning and procedural complications1/530/520/54
Bone marrow oedemaBlood and lymphatic system disorders0/530/521/54
Femur fractureInjury, poisoning and procedural complications0/530/521/54
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPlaceboPTC518 5 mgPTC518 10 mg
HeadacheNervous system disorders7/538/5213/54
FallInjury, poisoning and procedural complications5/538/5211/54
Back painMusculoskeletal and connective tissue disorders4/539/528/54
InfluenzaInfections and infestations9/537/529/54
NasopharyngitisInfections and infestations9/536/528/54
Post lumbar puncture syndromeInjury, poisoning and procedural complications3/535/523/54
DiarrhoeaGastrointestinal disorders3/534/525/54
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/533/525/54
COVID-19Infections and infestations3/532/524/54
Skin abrasionInjury, poisoning and procedural complications1/532/524/54

Baseline characteristics

Intent-to-treat (ITT) Population included all randomized participants who took at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)PlaceboPTC518 5 mgPTC518 10 mgTotal
Mean48.6 ± 9.5949.2 ± 9.0447.8 ± 9.1048.5 ± 9.20
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPTC518 5 mgPTC518 10 mgTotal
Female33262988
Male20262571
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPTC518 5 mgPTC518 10 mgTotal
Hispanic or Latino2316
Not Hispanic or Latino514953153
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboPTC518 5 mgPTC518 10 mgTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White524752151
More than one race0000
Unknown or Not Reported1427
08

Study locations

28 sites
  • University of California, San Diego
    La Jolla, California 92037, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • The University of Texas Health Science Center at Houston; McGovern Medical School
    Houston, Texas 77030, United States
  • University of Washington Department of Neurology
    Seattle, Washington 98195, United States
  • Monash Health
    Clayton, 3168, Australia
  • Westmead Hospital
    Sydney, 2145, Australia
  • Medical University Innsbruck
    Innsbruck, 6020, Austria
  • The Ottawa Hospital, Parkinson's and Movement Disorders Clinic
    Ottawa, K1Y 4E9, Canada
  • Centre Hospitalier Universitaire d'Angers
    Angers, 49100, France
  • Hôpital Universitaire de Marseille Hôpital de la Timone
    Marseille, 13385, France
  • Brain and Spine Institute Paris
    Paris, 75013, France
  • Charite University Medicine Berlin
    Berlin, 10117, Germany
  • Ruhr-Univ. Bochum St. Joseph-Hospital
    Bochum, 44791, Germany
  • George-Huntington-Institut
    Münster, 48149, Germany
  • Ulm University, UKU, Dep. of Neurology
    Ulm, 89081, Germany
  • Irccs Istituto Delle Scienze Neurologiche Di Bologna Uoc Clinica Neurologica
    Bologna, 40139, Italy
  • IRCCS Carlo Besta Neurological Institutte
    Milan, 20133, Italy
  • IRCCS Casa Sollievo della Sofferenza Research Hospital
    San Giovanni Rotondo, 71013, Italy
  • Leiden University Medical Center
    Leiden, 2333 ZA, Netherlands
  • University of Otago, New Zealand Brain Research Institute
    Christchurch, 8011, New Zealand
  • Hospital Universitario Cruces
    Barakaldo, 48903, Spain
  • Hospital de la Santa Creu I Sant Pau
    Barcelona, 8025, Spain
  • Hospital Universitario Burgos
    Burgos, 90550, Spain
  • Hospital Ramón y Cajal
    Madrid, 28034, Spain
  • The Barbery National Centre for Mental Health
    Birmingham, B15 2FG, United Kingdom
  • Cardiff University Schools of Medicine and Biosciences
    Cardiff, CF10 3AX, United Kingdom
  • UCL Queen Square Institute of Neurology National Hospital for Neurology and Neurosurgery
    London, WC1N 3BG, United Kingdom
  • Manchester University NHS Foundation Trust
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Estevez-Fraga C, Tabrizi SJ, Wild EJ. Huntington's Disease Clinical Trials Corner: March 2024. J Huntingtons Dis. 2024;13(1):1-14. doi: 10.3233/JHD-240017. PubMed 38489195 ↗
  • Estevez-Fraga C, Tabrizi SJ, Wild EJ. Huntington's Disease Clinical Trials Corner: November 2022. J Huntingtons Dis. 2022;11(4):351-367. doi: 10.3233/JHD-229006. PubMed 36463457 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Feb 2025, 32 months.

Results were first posted in Jan 2026, 11 months after primary completion.

Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 3, 2022
StartActual
Jun 3, 2022
Primary completionActual
Feb 7, 2025
CompletionActual
Jul 31, 2025
Results first posted
Jan 13, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05358717
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Jun 3, 2022
Primary completion
Feb 7, 2025
Completion
Jul 31, 2025
Results posted
Jan 13, 2026
Last update
Jun 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Votoplam

Start the discussion